CERN Radioisotope Facility

CERN Radioisotope Facility
Name	CERN Radioisotope Facility
Established	1960s
Location	Meyrin, Geneva, Switzerland
Type	Radioisotope production facility
Parent	CERN

CERN Radioisotope Facility is a specialized production and research installation at Meyrin associated with particle physics infrastructure. It synthesizes and supplies medical and industrial radioisotopes using accelerator and reactor-derived techniques, supporting nuclear medicine, radiopharmacy, and detector development. The facility interfaces with international partners and regulatory organizations to integrate isotope production with clinical trials, radiochemistry research, and material science programs.

Overview

The facility operates within the organizational framework of CERN and cooperates with institutions such as European Organization for Nuclear Research, European Association of Nuclear Medicine, World Health Organization, International Atomic Energy Agency, and national agencies like Swiss Federal Office of Public Health and Haute Autorité de Santé. It serves users from Geneva University Hospitals, University of Geneva, University of Oxford, Massachusetts General Hospital, and industrial partners including Siemens Healthineers and GE Healthcare. The production portfolio links to clinical networks such as European Society for Radiology and research infrastructures including European Molecular Biology Laboratory, Institut Laue–Langevin, and European XFEL.

History and Development

Origins trace to early collaborations between CERN and European hospitals inspired by postwar radioisotope initiatives led by figures connected to Enrico Fermi, Ernest Lawrence, and institutes like Atomic Energy Commission (France) and UK Atomic Energy Authority. Development accelerated alongside projects at Proton Synchrotron, Super Proton Synchrotron, and later Large Hadron Collider upgrades, leveraging accelerator beamtime similar to programs at Paul Scherrer Institute and TRIUMF. Milestones intersect with policy discussions at European Council meetings and technical exchanges at International Conference on Radiopharmaceutical Sciences.

Facility Infrastructure and Capabilities

Physical infrastructure includes hot cells, cyclotron beamline interfaces, radiochemistry laboratories, and cleanrooms comparable to those at Institut Curie, Karolinska Institute, and Johns Hopkins Hospital radiopharmacy units. Equipment comprises superconducting magnets akin to those in LHC, ion sources originally developed in collaboration with CERNIS, fractionation modules used by Novartis, and automated synthesis modules comparable to GE FASTlab. Analytical instruments include CERN-grade mass spectrometers, high-purity germanium detectors used in Compton Telescope projects, and radiochromatography suites employed by Oxford Radiocarbon Accelerator Unit. The site supports short-lived isotopes via on-site cyclotron operations similar to Arronax and longer-lived nuclides through sealed-source handling analogous to programs at Institut Laue–Langevin.

Radioisotope Production and Applications

Production focuses on medical isotopes such as fluorine-18 for positron emission tomography used at Mayo Clinic and University Hospital Zürich, technetium-99m analogues relevant to Royal Marsden Hospital, and emerging isotopes like scandium-44 and copper-64 pursued by Karolinska Institutet researchers. Industrial applications include non-destructive testing workflows employed by Airbus and environmental tracers used by European Space Agency projects. The facility supports radiopharmaceutical development tied to trials at European Medicines Agency-registered centers and oncology programs at Institut Gustave Roussy and Memorial Sloan Kettering Cancer Center. Collaborative isotope supply networks connect to Nuclear Medicine Society chapters and national health services such as National Health Service (England).

Safety, Regulation, and Waste Management

Operational governance aligns with regulations from International Atomic Energy Agency, European Commission, and national authorities including Swiss Federal Office of Public Health and Autorité de sûreté nucléaire (France). Safety systems mirror practices at Fukushima Daiichi decommissioning programs for containment planning and reference waste routes documented by Organisation for Economic Co-operation and Development nuclear agencies. Waste management integrates conditioning, interim storage, and transport compliant with International Air Transport Association and International Maritime Organization conventions, and collaborates with repositories such as Cigeo planning bodies. Emergency preparedness liaises with regional civil protection services like Etat de Genève authorities and hospital emergency departments at Hôpitaux Universitaires de Genève.

Research, Collaborations, and Clinical Impact

Research programs bridge radiochemistry, accelerator physics, and clinical oncology, partnering with universities including ETH Zurich, Imperial College London, Sorbonne University, and University of Cambridge. Collaborative projects have interfaced with initiatives like Human Brain Project, EU Horizon 2020, and translational programs at Cancer Research UK. Clinical impact is evidenced by tracer development adopted in trials at Vall d'Hebron Institute of Oncology and imaging protocols influenced by committees within European Association of Nuclear Medicine. The facility contributes technical expertise to detector R&D used in experiments such as ATLAS, CMS, ALICE, and supports isotope-enabled technologies for space missions coordinated with European Space Agency and NASA.

Category:Research facilities in Switzerland Category:Nuclear medicine Category:CERN